Loading
Lotus Pharm: what insiders have been doing
Lotus Pharm is a listed company. Its directors and officers file their transactions with TWSE / TPEx (MOPS). The last twelve months, up to 18 October 2026, brought 3 filings signed by 3 insiders.
Not one of the filings records a straightforward purchase or sale on the market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
For context, the typical company on the same exchange (median of 515 companies) published 2 filings over the same period, against 3 filings here.
Over the last twelve months, not one insider purchase of Lotus Pharm stock was filed. The median gap between trade and publication is zero days: most filings appear on the same day. The shorter that gap, the sooner other investors can see what insiders have done.
These figures are compiled from regulatory filings published by TWSE / TPEx (MOPS). They describe what insiders did and are not a recommendation.
Insider Decl.
3
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 4,691 of 24,158 companies
67.2
score / 100
Value69
Quality66
FCF yld6.5%
Earn yld9.8%
EV/EBITDA11.7x
ROE17%
Gross mgn58%
Net mgn23%
Debt/EBITDA5.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
NT$180
Analyst consensus
5 analystsNT$197Target NT$292(+62%)NT$494
Income statement
RevenueNT$20.5B
Gross profitNT$11.9B58% margin
EBITDANT$8.1B40% margin
Net incomeNT$4.7B13.2% margin
Valuation
PER (trailing)12.7x
PER (forward)7.6x
P/Book2.0x
Beta0.66
Balance sheet & cash
Market capNT$47.9B
Total debtNT$47.5B
Free Cash FlowNT$3.1B
Debt / Equity240%
Profitability & ownership
ROE16.9%
ROA6.2%
% insiders48.1%
% institutions7.9%
Last declaration on 23 September 2026
About Lotus Pharm
美時 is a company listed on the XTAI, specializing in the financial sector.